Position paper from the Indonesian Society of Thrombosis and Hemostasis (InaSTH), Semarang chapter: Management of coagulopathy in COVID-19

Pangarsa, Eko Adhi; Setiawan, Budi; Santosa, Damai; Naibaho, Ridho M.; Rizky, Daniel; Suyono, null; Tobing, Mika Lumban; Suharti, Catharina

doi:10.15562/bmj.v9i2.1841

Cited by 2 publications

(7 citation statements)

References 36 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Algoritma pemberian tromboprofilaksis pada pasien dengan COVID-19 yang diajukan oleh InaSTH Semarang. 23 SIC score adalah penilaian yang berguna untuk mendeteksi fase awal sebelum muncul DIC yang jelas. ISTH juga memiliki nilai skoring untuk DIC yang menambahkan penilaian D-dimer dan fibrinogen.…”

Section: Parameter Hemostasisunclassified

“…25 InaSTH Semarang mengajukan nilai batas D-dimer yang digunakan sebesar ≥3x batas atas normal. 23 Tabel 1. SIC score ISTH untuk mendiagnosis koagulopati diinduksi sepsis 24 .…”

Section: Parameter Hemostasisunclassified

“…Berdasarkan alur terapi InaSTH, tromboprofilaksis mekanik diberikan pada pasien dengan skor asesmen risiko perdarahan IMPROVE ≥7. 23 Sedangkan Thrombosis UK merekomendasikan tromboprofilaksis mekanik apabila jumlah platelet <30.000 atau apabila didapatkan perdarahan. 29…”

Section: Tromboprofilaksis Mekanikunclassified

“…Berdasarkan InaSTH, obat yang dapat digunakan sebagai antikoagulan terapeutik diantaranya adalah enoxaparin, nadroparin, fondaparinux, dan UFH. Untuk keperluan terapeutik, dosis yang digunakan secara umum lebih tinggi dibandingkan dengan pengobatan profilaksis (Tabel 4) 23 . Antikoagulan terapeutik diberikan selama 3 bulan bila pasien dapat mentoleransi terapi dengan baik tanpa perdarahan yang serius.…”

Section: Antikoagulan Terapeutikunclassified

“…23 Pada pasien yang mengalami sepsis dapat terjadi gangguan koagulasi. SIC score adalah sistem penilaian yang diajukan oleh ISTH untuk menilai adanya koagulopati yang diinduksi sepsis.…”

unclassified

See 4 more Smart Citations

Trombosis pada corona virus disease (COVID-19)

Sunggoro

Purwanto²,

Hasan³

2020

JKS

View full text Add to dashboard Cite

Abstrak. Coronavirus Disease 2019 (COVID-19) telah menyebabkan masalah kesehatan di seluruh dunia dengan morbiditas dan mortalitas yang terus meningkat. Pada beberapa kasus COVID-19 diketahui terjadi manifestasi trombotik. Adanya kelainan trombotik ini tentunya mempengaruhi tatalaksana dan prognosis pasien COVID-19. Oleh karena itu penting untuk mengetahui patofisiologi dan manajemen trombosis pada COVID-19. Tujuan dari artikel ini adalah mengulas literatur terbaru terkait prevalensi, patofisiologi, penilaian risiko, serta manajemen trombosis pada COVID-19.Kata kunci: COVID-19, trombosis.Abstract. Coronavirus Disease 2019 (COVID-19) has become a global health problem with ever increasing morbidity and mortality. In some cases, thrombotic manifestation has been reported in COVID-19 patients. This thrombotic manifestation certainly affects the management and prognosis of COVID-19 patients. Therefore it is crucial to understand the pathophysiology and management of thrombosis in COVID-19. The aim of this article is to review the recent literature regarding prevalence, pathophysiology, risk assessment, and management of thrombosis in COVID-19.Keywords:COVID-19, thrombosis

show abstract

Section: Parameter Hemostasisunclassified

“…25 InaSTH Semarang mengajukan nilai batas D-dimer yang digunakan sebesar ≥3x batas atas normal. 23 Tabel 1. SIC score ISTH untuk mendiagnosis koagulopati diinduksi sepsis 24 .…”

Section: Parameter Hemostasisunclassified

Section: Tromboprofilaksis Mekanikunclassified

Section: Antikoagulan Terapeutikunclassified

“…23 Pada pasien yang mengalami sepsis dapat terjadi gangguan koagulasi. SIC score adalah sistem penilaian yang diajukan oleh ISTH untuk menilai adanya koagulopati yang diinduksi sepsis.…”

unclassified

See 3 more Smart Citations

Trombosis pada corona virus disease (COVID-19)

Sunggoro

Purwanto²,

Hasan³

2020

JKS

View full text Add to dashboard Cite

show abstract

Analysis of Enoxaparin Effectiveness Based on COVID-19 Severity: A Study in a Secondary Hospital in Bandung, Indonesia

Suprapti

Debora²,

Kusumawati³

et al. 2022

Indonesian J Pharm

View full text Add to dashboard Cite

Li Coagulopathy is a common predictor of mortality in COVID-19. Meanwhile, enoxaparin is an anticoagulant with anti-inflammatory, endothelial protection, and viral antagonist properties. Therefore, thromboprophylaxis with enoxaparin in COVID-19 is common in clinical settings. This study aims to assess enoxaparin's efficacy across different severity levels by examining its effect on primary outcomes comprising Length of stay (LOS), invasive mechanical ventilation, and mortality as well as secondary in the form of D-dimer, platelets, C-reactive protein (CRP), Neutrophil Lymphocyte Ratio (NLR), and Absolute Lymphocyte Count (ALC). During hospitalization, 269 patients received enoxaparin across varying severity levels comprising mild, moderate, and severe, while the Wilcoxon test was used to analyze the efficacy in each group. Additionally, the differences in patient characteristic profiles across the severity levels were determined using the Kruskal-Wallis test. The increase in mortality rate and the need for mechanical ventilation were directly proportional to the level of severity. D-dimer decreased from 1308.87 ng/ml to 979.83 ng/ml (p=<0,001) as well as from 1758.41 ng/ml to 1510.68 ng/ml (p=<0,001) in the mild and moderate levels respectively. The platelet increased from 225.65 to 369.39 x103/µl (p=<0,001) in mild and 256.77 to 398.97 x103/µl (p=<0,001) in moderate. Moreover, CRP improved in both mild 52.62 to 49.58 mg/l (p=0.031) and moderate 92.99 to 42.66 mg/l, (p=<0,001). Based on the results, enoxaparin effectively improves D-dimer, platelet, and CRP levels in mild and moderate but not in severe conditions, however, no effect was found on LOS, NLR, and ALC.

show abstract

Position paper from the Indonesian Society of Thrombosis and Hemostasis (InaSTH), Semarang chapter: Management of coagulopathy in COVID-19

Cited by 2 publications

References 36 publications

Trombosis pada corona virus disease (COVID-19)

Trombosis pada corona virus disease (COVID-19)

Analysis of Enoxaparin Effectiveness Based on COVID-19 Severity: A Study in a Secondary Hospital in Bandung, Indonesia

Contact Info

Product

Resources

About